Androgen-independent prostate cancer progression in the TRAMP model - PubMed (original) (raw)

. 1997 Nov 1;57(21):4687-91.

Affiliations

PMID: 9354422

Androgen-independent prostate cancer progression in the TRAMP model

J R Gingrich et al. Cancer Res. 1997.

Abstract

We previously established the autochthonous transgenic adenocarcinoma mouse prostate (TRAMP) model to facilitate characterization of molecular mechanisms involved in the initiation and progression of prostate cancer. TRAMP mice display high grade prostatic intraepithelial neoplasia or well-differentiated prostate cancer by 10-12 weeks of age. To test the hypothesis that molecular events leading to androgen independence and metastasis can occur early in the natural history of prostate cancer yet remain silent until selective pressures such as androgen deprivation are applied, we have examined the consequences of castration on the initiation and progression to metastatic prostate cancer in TRAMP mice. Cohorts were castrated at 12 weeks of age and sacrificed at 18 (T12/18) or 24 (T12/24) weeks of age, and the development of primary cancer and metastatic disease was compared to noncastrated (T18 and T24) controls. Median T12/18 and T12/24 genitourinary (GU) weight was significantly less than T18 and T24, respectively. In addition, T12/24 GU weight was significantly greater than T12/18. Histological prostate tumors developed in 3 of 7 T12/18 and 8 of 10 T12/24 mice. All tumors that developed in castrated mice were poorly differentiated in contrast to 27% in noncastrated controls. Although castration significantly decreased GU tumor burden, overall progression to poorly differentiated and metastatic disease was not ultimately delayed. These results demonstrate that prostate cancer in the TRAMP model is heterogeneous with respect to androgen dependence as early as 12 weeks of age; therefore, early androgen ablation may have a variable impact on progression in an individual mouse. Further analysis of this prostate cancer model to identify specific molecular mechanisms that determine androgen sensitivity may facilitate future initiation of appropriate individualized hormonal therapy for the management of human prostate cancer.

PubMed Disclaimer

Cited by

Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models.
Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R. Sun J, et al. Metabolites. 2021 Feb 26;11(3):139. doi: 10.3390/metabo11030139. Metabolites. 2021. PMID: 33652703 Free PMC article.
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.
Irshad S, Abate-Shen C. Irshad S, et al. Cancer Metastasis Rev. 2013 Jun;32(1-2):109-22. doi: 10.1007/s10555-012-9409-1. Cancer Metastasis Rev. 2013. PMID: 23114843 Free PMC article. Review.
Rebuilding cancer metastasis in the mouse.
Saxena M, Christofori G. Saxena M, et al. Mol Oncol. 2013 Apr;7(2):283-96. doi: 10.1016/j.molonc.2013.02.009. Epub 2013 Feb 20. Mol Oncol. 2013. PMID: 23474222 Free PMC article. Review.
Prostate cancer stem cells.
Tu SM, Lin SH. Tu SM, et al. Clin Genitourin Cancer. 2012 Jun;10(2):69-76. doi: 10.1016/j.clgc.2012.01.002. Epub 2012 Mar 14. Clin Genitourin Cancer. 2012. PMID: 22421313 Free PMC article. Review.
Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer.
Adhami VM, Mukhtar H. Adhami VM, et al. Mol Biotechnol. 2007 Sep;37(1):52-7. doi: 10.1007/s12033-007-0047-8. Mol Biotechnol. 2007. PMID: 17914164 Review.

Androgen-independent prostate cancer progression in the TRAMP model - PubMed (original) (raw)